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Bombesin (BN), a tetradecapeptide originally isolated from
amphibian skin in 1970, has potent hypertensive and gastrin-
releasing effects in mammals (Erspamer et al, 1970; Erspamer et
al, 1972a,b). Its homologue, gastrin-releasing peptide (GRP), is a
27-amino-acid peptide (McDonald et al, 1979) that is highly
conserved in amphibian, avian, canine, rat and human species
(McDonald et al, 1980; Reeve et al, 1983; Orloff et al, 1984;
Zoeller et al, 1989; Nagalla et al, 1992). A fully active decapeptide
identical to the C-terminus of GRP (GRP 18–27) has also been
isolated from porcine and human tissue (Minamino et al, 1984;
Orloff et al, 1984). GRP-like immunoreactivity (GRP-LI) and
receptor binding is distributed predominantly in the brain, spinal
cord, gut and lung, where it is thought to act both as a growth
factor and as a neuroregulatory hormone (Moody et al, 1980;
Sunday et al, 1988).
GRP has been detected in 60–70% of small-cell lung cancers
(SCLC) (Wood et al, 1981; Yamaguchi et al, 1983; Bostwick et al,
1984), and GRP receptors have been demonstrated in numerous
SCLC cell lines (Moody et al, 1983). In addition, the involvement
of GRP as an autocrine growth factor in SCLC is well established
(Cuttitta et al, 1985). This prompted a vast research effort to
develop GRP receptor antagonists as a potential treatment for
SCLC. More recently, evidence has been accumulating to suggest
that GRP may play a role in the growth of breast cancer cells. GRP-
LI has been detected in a proportion of breast tumours (Foster and
Tan, 1984; Gaudino et al, 1986; McKillop et al, 1988) but not in
normal tissues (Bostwick and Bensch, 1985; Gaudino et al, 1986).
Using Northern blotting, GRP mRNA has been detected in 25% of
unselected primary breast tumours (Pagini et al, 1991). More
recently, Vangsted et al (1991) detected GRP-LI in 39% of primary
breast tumours from post-menopausal women. GRP-LI has been
detected in a number of established breast cancer cell lines accom-
panied by much higher levels of the C-terminal extension peptide
(CTEP) (Weber et al, 1989; Vangsted et al, 1991; Yano et al, 1992).
GRP receptors have been described in breast cancer cell lines T47D
and MDA-MB-436 (Giacchetti et al, 1990). Previously, we have
shown that both BN and GRP stimulate proliferation of breast
cancer cell lines when culture serum has been stripped of endoge-
nous GRP-like peptides (Nelson et al, 1991); other workers have
confirmed these findings (Yano et al, 1992).
The cell-surface enzyme neutral endopeptidase EC 24.11 (EC
3.4.24.11), known to be involved in the catabolism and inactiva-
tion of a number of neuropeptides in the brain and GI tract (Relton
et al, 1983; Matsas et al, 1984), has also been shown to hydrolyse
and inactivate GRP (Bunnett et al, 1988). This enzyme inactivates
GRP and GRP18–27 by cleaving the His25–Leu26 bond; the
His20–Trp21 bond is also cleaved, but to a much lesser extent
(Bunnett et al, 1988). Other work suggests that high levels of
neutral endopeptidase EC 24.11 regulate GRP-mediated growth 
of fetal lungs (King et al, 1993), and there is also considerable
evidence that this enzyme regulates extracellular GRP levels in
SCLC cell lines. Colony formation in SCLC cell lines that secrete
GRP-like peptides is potentiated when neutral endopeptidase EC
24.11 is inhibited using phosphoramidon. This increase in colony
formation is reduced in the presence of GRP receptor antagonists,
indicating that a major role of neutral endopeptidase EC 24.11 is to
reduce the activity of secreted GRP-like peptides (Shipp et al,
1991). Decreased EC 24.11 expression in prostatic cancer cell
lines has been correlated with increased growth response to
bombesin, as well as progression to an androgen-independent
phenotype (Papandreou et al, 1998).
Given the reports that GRP is degraded locally in both normal
and neoplastic tissues and the mounting evidence that GRP-like
peptides may act as growth factors in human breast cancer, we
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have investigated the possibility that these cells also possess
neutral endopeptidase on their cell surface. Here, we report the
presence of an EC 3.4.24.11-like enzyme on the surface of breast
cancer cells. The growth of these cells and their response to
bombesin was also greatly enhanced in the presence of the EC
3.4.24.11 selective inhibitor phosphoramidon.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle medium (DMEM), RPMI-1640 and L-
15 media were obtained from Flow Laboratories, Irvin, UK; fetal
calf serum (FCS) and trypsin were purchased from Gibco, Paisley,
UK. Phosphoramidon, anti-rabbit immunoprecipitation reagent, 
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT), leucine aminopeptidase and the enzyme inhibitors
isopropyl difluorophosphate, iodoacetamide and pepstatin were
obtained from Sigma Chemical Co, Poole, Dorset, UK. The fluoro-
genic substrate N-succinyl-Ala-Ala-Phe-AMC (AAP-AMC) and
bombesin were obtained from Novabiochem, Nottingham, UK.
The specific elastase inhibitor was synthesized according to the
method previously published (Oleksyszyn and Powers, 1991).
Cell culture
The T47D (Keydar et al, 1979), ZR-75-1 and MDA-MB-436
breast cancer cell lines were obtained from the European
Collection of Animal Cell Cultures, Porton Down, UK. The SCLC
H345 cell line was obtained from Imperial Cancer Research Fund
Laboratories, London, UK. The T47D and H345 cell lines were
maintained in DMEM supplemented with 10% FCS and 10% heat-
inactivated FCS respectively. The ZR-75-1 cells were maintained
in RPMI-1640 medium supplemented with 5% FCS, and the
MDA-MB-436 cells were maintained in L-15 medium supple-
mented with 10% FCS. Cells were routinely passaged when
subconfluent using 2 ml of 2.5 mg ml–1 trypsin in calcium-free
saline (0.14 M sodium chloride, 5 mM potassium chloride, 4 mM
sodium hydrogen carbonate, 5 mM glucose).
Growth studies
After trypsinization, cells were inoculated into 96-well plates at
1 ´ 104 cells per well in medium used for routine passaging.
After 24 h, the medium was removed and the treatments added
in medium containing heat and dextran-coated charcoal-treated
FCS (HT and DCC FCS) prepared as detailed previously (Nelson
et al, 1987, 1991). Treatments were either control (medium only),
0.001–100 nM bombesin or 0.001–100 nM bombesin in the pres-
ence of phosphoramidon (0.1–100 ng ml–1). For cell enumeration,
a modification of the MTT assay (Twentyman and Luscombe,
1987) was used as follows; 10 ml of 3-(4,5-dimethylthiazole-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT 20 mg ml–1) was added to
each well and incubated for 2 h at 37°C, the medium was removed
and the formazan crystals were solubilized in 0.2 ml of DMSO.
The colour intensity was then measured at 510 nm using a Titertek
Multiscan plate reader.
Preparation of cells and conditioned media for
radioimmunoassay (RIA)
Preconfluent flasks (90%) were incubated in serum-free media for
24 h, the conditioned medium was removed and centrifuged at
2500 g for 10 min and stored at –20°C before Sep-Pak extraction.
Cells were removed from monolayer by scraping and washed in
serum-free medium and frozen at –20°C. The extraction procedure
used for the cell pellets is a modification of that described previ-
ously by Gaudino et al (1986). Cells were washed in ice-cold
extraction buffer (50 mM Hepes, 5 mM magnesium chloride, 
1 mg ml–1 bacitracin and 10 mg ml–1 phosphoramidon) and boiled
for 10 min in 10% formic acid. The extracts were neutralized and
clarified by centrifugation at 3800 g for 15 min. The supernatants
and conditioned media were desalted and concentrated using 
Sep-Pak C18 elution as follows; cartridges were pre-wet with 10
ml each of water, ethanol and 0.05% trifluoroacetic acid (TFA),
the sample was passed through the cartridge three times. After
washing with 0.05% TFA, the peptides were eluted with 80%
acetonitrile containing 0.05% TFA. Positive controls in which
[125I]GRP was added to cell pellets showed a 79% recovery of 
radioligand from the cartridge. The eluent was lyophilized and
frozen. Immediately before measurement, the residue was
dissolved in RIA assay buffer.
HPLC analysis of cell extracts
Reverse phase high-performance liquid chromatography (HPLC)
analysis was carried out using Delta-Prep System (Waters
Associates) fitted with a mBondpak C18 analytical column. Buffer
A was deionized water containing 0.05% trifluoroacetic acid,
initially at 98% decreased to 0% after 25 min. Buffer B comprised
acetonitrile containing 0.05% trifluoroacetic acid, started at 2%
and increased to 65% after 25 min. The solvent flow rate was 
1 ml min–1 and samples were collected over a period of 1 min.
Three runs were performed and eluents for corresponding intervals
were pooled and lyophilized and stored at –20°C before radio-
immunoassay.
Radioimmunoassay
This assay utilized a rabbit GRP18–27 antiserum raised by this group
and described previously (Walker et al, 1995). Five thousand
c.p.m. of [125I]GRP at a 1:1000 dilution of the antisera and stan-
dards or unknown samples were added in duplicate to siliconized
Eppendorf tubes in a final volume of 0.2 ml of radio-immunoassay
buffer (50 mM sodium phosphate, 10 mM EDTA and 0.3% RIA-
grade bovine serum albumin, pH 7.4). A blank (no antiserum) and
a standard curve with 0–1000 fmol per tube GRP18–27 was set up
for each test. After 24 h incubation at 4°C, bound radioligand was
immunoprecipitated by anti-rabbit immunoprecipation reagent for
2 h at room temperature and centrifuged at 7500 g for 15 min. The
supernatant was removed and bound radioligand was counted for 1
min in a LBK gamma-counter.
Fluorogenic enzyme assay
EC 24.11 activity was measured in whole-cell suspensions in a
coupled assay using N-succinyl-Ala-Ala-Phe 7-amido-4-methyl-
coumarin (AAP-AMC) as substrate. Cells were removed from
flasks by scraping, washed in phosphate-buffered saline (PBS) and
suspended in fluorogenic assay buffer (0.1 M sodium phosphate
buffer, pH 7.5, with 0.05% Brijj) at 1 ´ 10–4 cells ml–1 before
experiment. Thirty-six units (140 U mg–1 protein) of leucine
aminopeptidase (EC 3.4.11.1) from porcine kidney and N-
succinyl-Ala-Ala-Phe-AMC (AAP-AMC) were added to the216 DM Burns et al
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cuvette to give a final concentration of 10 mM in a final volume of
1.0 ml. The reaction was initiated by the addition of an appropriate
number of whole cells in fluorogenic assay buffer. Samples were
excited at 383 nm and emission was measured at 455 nm.
Production of fluorogenic product at room temperature was
measured for 10 min using a Perkin-Elmer fluorimeter model
LS50B. Specificity of the assay was tested by performing the
following negative controls before each experiment: AAP-AMC
alone; AAP-AMC and leucine aminopeptidase; and AAP-AMC
with leucine aminopeptidase and cells suspension. Inhibitors were
incubated in the presence of cells for 30 min before addition of
AAP-AMC and leucine aminopeptidase and the assay.
Statistical analysis
Control and treatment data from the growth studies were
compared using an unpaired Student’s t-test.
RESULTS
Measurement of GRP-LI in breast cancer cell lines
RIA was performed on the breast cancer cell lines T47D, ZR-75-1
and MDA-MB-436 cell pellets and their conditioned medium. The
T47D cells were found to contain 1.09 pmol GRP-LI per 107 cells
and dilutions paralleled the standard curve (Figure 1). Conditioned
medium from the T47D cells, however, did not contain any GRP-
LI. Immunoreactivity was not detected in ZR-75-1, MDA-MB-
436, Cos-7 or A431 cell lines or their conditioned medium.
The immunoreactivity detected in the T47D cells was further
investigated using reversed-phase HPLC. A minor peak eluted
after 6 min, however the vast majority eluted in a sharp peak after
20 min. This corresponds very closely with the elution time of
19.5 min for GRP18–27 (Figure 2).
Effect of phosphoramidon on BN-induced cell growth
MTT assays were set up to examine the effect of 0.1–100 ng ml–1
phosphoramidon alone and in combination with 0.1 nM BN on the
T47D cells in HT and DCC FCS (Figure 3). After 3 days, 1–
100 ng ml–1 of the inhibitor gave a marked inhibition (19–35%) of
cell growth alone. This dose range of phosphoramidon also
dramatically potentiated the response of these cells to BN.
Whereas BN alone showed a small increase in cell number after 3
days, in this instance it was not statistically significant. However,
in combination with 0.1–100 ng ml–1 phosphoramidon the cell
growth was markedly increased. Phosphoramidon (0.1 ng ml–1 and
1 ng ml–1) gave a 38% and 30% increase in BN-induced growth
respectively. Phosphoramidon (0.1 ng ml–1) appeared to be a
threshold dose above which higher concentrations of inhibitor
produced no increased effect. When compared with cell numbers
in the presence of 1 ng ml–1 phosphoramidon alone, 0.1 nM BN in
combination with phosphoramidon produced an increased growth
of 132% (P < 0.01).
400 0 300 100 200 500 600
80
60
40
20
0
120
100
%
B
/
B
O
GRP18–27 (fmol per tube)
Figure 1 Radioimmunoassay standard curve for GRP 18–27 –m– and T47D
cell extract  –l–. [125I]GRP (5000 c.p.m.) and antiserum at final dilution of
1:1000 per tube were used and incubations were performed at 4°C for 
24 h. Data points represent the means of duplicate tubes
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Figure 2 Reverse-phase HPLC separation of T47D cell extract followed by
GRP radioimmunoassay of fractions. Elution buffer was acetonitrile
containing 0.05% trifluoroacetic acid starting at 2% and increasing to 65%
after 25 min. Eluents from corresponding fractions were pooled from three
runs and lyophilized before radioimmunoassay. Elution time of GRP 18–27 is
indicated by an arrow
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Figure 3 The effect of phosphoramidon –l–, and phosphoramidon in the
presence of bombesin (0.1 nM) –m– on the growth of T47D cells after 3 days
in DMEM +10% HT and DCC-treated FCS. Results are the mean optical
density + s.d. for eight wells. **P < 0.01 vs phosphoramidon only in Student’s
t-testBreast cancer cell-associated neutral endopeptidase 24.11 217
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Fluorogenic measurement of EC 3.4.24.11
For all experiments, the substrate alone produced baseline fluor-
escence indicating that there was no autohydrolysis. Similarly, the
substrate in the presence of leucine aminopeptidase (LAP)
produced baseline fluorescence eliminating the possibility of
enkephalinase contamination of the LAP. The SCLC cell line
H345 was found to produce a turnover of substrate of 303.6 pmol
per 106 cells h–1. This activity was reduced by 76.6% in the pres-
ence of phosphoramidon. The T47D cells exhibited a much lower
turnover of substrate with 4.6 pmol per 106 cells h–1 being recorded
alone with 56% of this activity being phosphoramidon sensitive.
The inhibitors DFP (0.5 mM), iodoacetamide (10 mM) and
pepstatin (10 mM) did not inhibit substrate turnover. In the pres-
ence of the elastase inhibitor Z-Val-diphenyl phosphonate
(43 mM), a small inhibition was recorded (data not shown).
DISCUSSION
It is widely accepted that SCLC tumours arise from endocrine
cells because they display characteristics such as amine precursor
uptake and decarboxylation (APUD) staining and contain several
neuropeptides (Baylin et al, 1980; Gazdar et al, 1980; Marangos et
al, 1982). Some of these neuropeptides, including bombesin, have
been shown to act as autocrine growth factors in numerous SCLC
cell lines (Cuttitta et al, 1985; Bepler et al, 1988; Sethi and
Rozengurt, 1991). Unlike SCLC, the vast majority of breast
cancers are epithelium-derived tumours, with only 5% being esti-
mated to be carcinoids with a neuroendocrine origin (Papotti et al,
1989). These tumours are reported to be strongly immunoreactive
for GRP-LI (Nesland et al, 1985; Pagini et al, 1991). The presence
of neuropeptides in a large proportion of breast tumours would,
therefore, be unexpected, however, in at least one study mRNA for
GRP was detected in 25% of unselected breast tumours and it had
poor correlation with neuroendocrine differentiation (Pagini et al,
1991). Interestingly, GRP-LI has also been reported in breast milk
in a number of studies (Ekman et al, 1985; Westrom et al, 1987).
Thus, the presence of GRP in breast cancer cells may instead be
due to lactational differentiation, a phenomenon which is known to
occur in breast carcinomas (Clayton et al, 1982; Lee et al, 1984;
Baildam et al, 1988).
The occurrence of GRP-LI in breast cancer cell lines is not
without controversy. Although it has been detected in T47D cells
in this study and by Vangsted et al (1991), Northern blot analysis
for prepro-GRP mRNA has been negative (Giachetti et al, 1990;
Pagini et al, 1991). This lack of correlation between GRP
immunoreactivity and mRNA detection is observed in other
tumour types (Hamid et al, 1987, 1989), and has been attributed to
antisera cross-reactivity with related neuropeptides (Pagini et al,
1991). Alternatively, detection of a low-abundance mRNA for this
peptide may require reverse transcription polymerase chain reac-
tion (RT-PCR) and this was not carried out in the studies on breast
cancer cell lines (Giachetti et al, 1990; Pagini et al, 1991). Hence,
it is important to further characterize this immunoreactivity. In this
study, HPLC analysis strongly suggests the major peak is GRP18–27
because it co-eluted with this standard. This is in agreement with
similar chromatographic analysis performed by Vangsted et al
(1991). The minor, more hydrophilic peak may represent a larger
peptide, perhaps GRP. Failure to detect GRP-LI in conditioned
medium from T47D cell-conditioned medium here and by
Vangsted et al (1991) suggests that it is rapidly cleared from the
extracellular surface. Of importance is the fact that the C-terminal
extension peptide (CTEP), which is cleaved from prepro-GRP
during processing, has been found in the T47D-conditioned
medium in the absence of the mature peptide (Vangsted et al,
1991). Accumulation of a similar stable CTEP has also been
described in SCLC cell lines (Vangsted and Schwartz, 1990). The
processing and subsequent degradation of the prepro-GRP moiety
clearly happens extracellularly in both cancer cell types.
Inhibition of fluorogenic substrate hydrolysis by phospho-
ramidon is a well-documented specific test for EC 3.4.24.11
activity (Hudgin et al, 1981; Shipp et al, 1991; Frame et al, 1996).
The demonstration that T47D whole cell-mediated turnover of
AAP-AMC is sensitive to phosphoramidon strongly suggests the
presence of the membrane-bound endopeptidase EC 3.4.24.11 on
these cells. In the growth studies, after 3 days all concentrations of
phosphoramidon tested (0.1–100 ng ml–1) enhanced BN-induced
growth. At this time, 1–100 ng ml–1 phosphoramidon alone inhib-
ited growth, however the reason for this is unclear at present. In
other tissues, EC 3.4.24.11 has been shown to degrade a range 
of peptides including enkephalins, substance P, bradykinin,
endothelin and angiotensin I and II (Matsas et al, 1984;
Vijayaraghavan et al, 1990). Although only endothelin (which is
not mitogenic) has been shown to be produced by the T47D cells
(Schrey et al, 1992), the possibility of other as yet unidentified EC
3.4.24.11-labile growth factors being expressed by the T47D cells
cannot be ruled out. Previous work in this laboratory found BN to
be mitogenic for breast cancer cell lines in vitro, with 0.001–
0.1 nM giving significant growth stimulation in the T47D cells
(Nelson et al, 1991). The potentiation of BN-induced growth by
phosphoramidon after 3 days is likely to be due to a prolonged
half-life of the peptide in the medium.
The fluorogenic assay found that there was approximately 100-
fold more EC 3.4.24.11 activity on the H345 SCLC cell line
compared with the T47D cells. This may be an explanation for the
difference in BN dose required for mitogenesis in cell lines from
these two cancer types. GRP/BN-stimulated colony formation is
maximal at 50 nM in SCLC cells, but in the breast cancer cells
significant stimulation is observed in the picomolar range in this
laboratory (Carney et al, 1981; Nelson et al, 1991). However, this
variation in mitogenicity may also be due to differing numbers of
BN/GRP receptors on these cell lines. Variations in the mitogenic
response to BN/GRP have been also observed between the clas-
sical and variant SCLC cell lines, this may be due to differing
numbers of GRP receptors reported on these cell lines (Kado-Fong
and Malfoy, 1989; Cardona et al, 1991). Stimulation of growth of
breast cancer cells by BN has also been confirmed by other
workers under serum-free or HT and DCC FCS conditions. In all
these studies, no effect was found in medium supplemented with
untreated FCS. A soluble form of EC 3.4.24.11 has been described
in urine, plasma and breast cyst fluid, but routine culture FCS to
date has not been investigated. Although the lack of response to
BN in untreated FCS has been attributed to the presence of
endogenous GRP-LI which is removed by HT and DCC treatment,
the role of a soluble EC 3.4.24.11 in FCS is yet to be studied.
These findings have practical implications for experimental
research in bombesin-like peptides and breast cancer. Firstly,
failure to inhibit EC 24.11-like activity in the past may have
compromised RIA or immunocytochemistry sensitivity, however
all the buffers used for cell homogenization for RIA and HPLC in
this study contained phosphoramidon. Secondly, binding of ligands
in radioreceptor studies on breast cancer cell lines could be signifi-218 DM Burns et al
British Journal of Cancer (1999) 79(2), 214–220 © Cancer Research Campaign 1999
cantly reduced because phosphoramidon was found to greatly
increase binding of [125I]GRP to SCLC cells (Cardona et al, 1992).
Extensive research efforts have been employed in the develop-
ment and evaluation of GRP receptor antagonists as potential treat-
ments for SCLC and, more recently, pancreatic, prostatic, gastric,
colorectal and breast cancer (Jungwirth et al, 1997; Nagy et al,
1997). The presence of EC 24.11-like activity on breast cancer
cells is a crucial consideration in the design of GRP receptor
antagonists. Whereas the sissile bonds and the relative rates of
hydrolysis have been identified for GRP and its homologues, to
date none of these antagonists have been evaluated for resistance
to cleavage by the enzyme.
EC 24.11 has been described on human endometrium, where
levels vary through the menstrual cycle but activity correlates with
plasma progesterone levels (Casey et al, 1991; Head et al, 1993).
More recently, reduced EC.24.11 mRNA expression has been
demonstrated on endometrial cancer cells compared with normal
endometrial tissue (Pekonen et al, 1995). Levels of this enzyme are
also reported to be 70–90% reduced on SCLC cell lines (Shipp 
et al, 1991). Additionally, EC 24.11 loss appears to play a role 
in the development of androgen-independent cells by allowing
neuropeptides such as GRP to enhance growth (Papandreou et al,
1998). Thus, reduced clearance of peptides may be the aberrant
factor which results in increased growth response of cancer cells.
Therefore, the concept of measuring peptidases in tumours may be
complementary to assessing growth factor levels as indicators of
tumour growth or progression.
This is the first indication of the presence of such an enzyme on
human breast cancer cells and supports the finding that GRP is an
autocrine growth factor in the T47D cells. It is possible that
reduced activity of this enzyme accompanies breast tumorigenesis
because levels in breast cysts decreased in those women who carry
a higher risk of future breast cancer when compared with those
who are not associated with any subsequent increase in incidence
(Frame et al, 1996).
In normal tissues, EC 3.4.24.11 has a diverse distribution, but is
usually found on cells bearing specific receptors for the multiple
possible target peptides. In the brain, it is responsible for the inac-
tivation of the enkephalins (Malfroy et al, 1978), whereas in lung it
down-regulates neurogenic inflammation by reducing local levels
of tachykinins (Martins et al, 1990; Nadel, 1990; Nadel and
Borson, 1991). It is also responsible for control of GRP-induced
growth in fetal lung, where alterations in levels of GRP throughout
maturation are accompanied by corresponding changes in EC
3.4.24.11 levels (King et al, 1993).
Given that GRP-like peptides are present in high amounts in
breast milk, it is probable that an enzyme would also control these
levels locally. EC 3.4.24.11 may also be present on normal breast
cells in a similar manner to normal lung tissue as Gusterson et al
(1985) reported specific staining for the CALLA antigen on
normal human breast sections. This antigen has subsequently been
shown to be identical to EC 3.4.24.11 (Ship et al, 1989). It, there-
fore, would be of interest to determine whether EC 3.4.24.11 or
GRP-like peptides played a modulatory role in normal breast
development.
In conclusion, this study demonstrates the production of a
GRP18–27 peptide by T47D breast cancer cells, but not by ZR-
75-1 or MDA-MB-436. This peptide is rapidly processed, degraded
and inactivated in the extracellular medium. A previously unre-
ported enzyme with an EC 3.4.24.11 profile on the human breast
cancer cell line T47D is also detected. Although this enzyme is
present at low levels, it significantly modulates the growth of the
T47D cells both alone and in response to BN in vitro.
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